|
市場調査レポート
商品コード
1578307
抗凝固薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測Global Anticoagulant Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
||||||
カスタマイズ可能
|
|||||||
| 抗凝固薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測 |
|
出版日: 2024年09月01日
発行: Value Market Research
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 図表
- 目次
抗凝固薬市場の世界需要は、調査期間2024-2032年のCAGR 9.39%で、2023年の401億米ドルから2032年には約899億5,000万米ドルの市場規模に達すると推定されます。
一般に血液希釈剤と呼ばれる抗凝固薬は、血液の凝固を阻害または抑制し、血液凝固期間を延長する化学物質です。抗凝固薬は体内で血栓ができる可能性をなくすために使用されます。血栓は、血小板が互いに接着し、血液中に存在するタンパク質が結合して固い塊を作ることで作られます。抗凝固薬は、血小板が互いに結合するのを阻止し、凝固タンパク質が互いに付着するのを阻止します。市場には様々なタイプの抗凝固薬があり、各薬剤は血液凝固の様々な経路を阻止することで機能します。これらの薬剤は主に、血栓、深部静脈血栓症、肺塞栓症などの脅威が高い場合に使用されます。そのほか、肺塞栓症、心房細動の治療、脳卒中のリスク管理にも一般的に使用されています。
市場力学
世界の抗凝固薬市場は、静脈血栓塞栓症や心血管疾患などの疾患が世界中で増加していることから、今後数年間は大幅な成長が見込まれています。さらに、新しい経口抗凝固薬の採用が増加し、新しい技術に対する認識が成熟していることも、市場の成長を後押ししています。同様に、現代的な治療薬に対する需要の高まりに伴う肥満問題の拡大と老年人口は、予測期間中の世界の抗凝固薬市場の成長に影響を与えると予測されています。
調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、抗凝固薬の世界市場における各セグメントを包括的に評価することもできます。抗凝固薬産業の成長と動向は、この調査に全体的なアプローチを提供します。
特注のご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。
目次
第1章 序文
第2章 エグゼクティブサマリー
- 市場のハイライト
- 世界市場スナップショット
第3章 抗凝固薬- 産業分析
- イントロダクション：市場力学
- 市場促進要因
- 市場抑制要因
- 市場機会
- 業界動向
- ポーターのファイブフォース分析
- 市場の魅力分析
第4章 バリューチェーン分析
- バリューチェーン分析
- 原材料分析
- 原材料リスト
- 原材料メーカーリスト
- 主要原材料の価格動向
- 潜在的バイヤーリスト
- マーケティングチャネル
- ダイレクトマーケティング
- インダイレクトマーケティング
- マーケティングチャネル発展動向
第5章 抗凝固薬の世界市場分析：薬剤カテゴリー別
- 概要
- 実績および予測データ
- 薬剤カテゴリー別分析
- 新規経口抗凝固薬（NOACs）（エリキス、ザレルト、サベイサ＆リクシアナ、プラザキサ）
- ビタミンK拮抗薬
- 直接トロンビン阻害薬
- ヘパリンおよび低分子ヘパリン（LMWH）
- その他
第6章 抗凝固薬の世界市場分析：投与経路別
- 概要
- 実績および予測データ
- 投与経路別分析
- 経口抗凝固薬
- 注射用抗凝固薬
第7章 抗凝固薬の世界市場分析：用途別
- 概要
- 実績および予測データ
- 分析：用途別
- 心房細動／心筋梗塞（心臓発作）
- 深部静脈血栓症（DVT）
- 肺塞栓症
- その他
第8章 抗凝固薬の世界市場分析：地域別
- 地域別展望
- イントロダクション
- 北米売上分析
- 概要、実績と予測
- 北米セグメント別
- 北米国別
- 米国
- カナダ
- メキシコ
- 欧州売上分析
- 概要、実績と予測
- 欧州セグメント別
- 欧州国別
- 英国
- フランス
- ドイツ
- イタリア
- ロシア
- その他欧州
- アジア太平洋地域売上分析
- 概要、実績と予測
- アジア太平洋地域セグメント別
- アジア太平洋地域国別
- 中国
- インド
- 日本
- 韓国
- オーストラリア
- 東南アジア
- その他アジア太平洋地域
- ラテンアメリカ売上分析
- 概要、実績と予測
- ラテンアメリカセグメント別
- ラテンアメリカ国別
- ブラジル
- アルゼンチン
- ペルー
- チリ
- その他ラテンアメリカ
- 中東・アフリカ売上分析
- 概要、実績と予測
- 中東・アフリカセグメント別
- 中東・アフリカ国別
- サウジアラビア
- アラブ首長国連邦
- イスラエル
- 南アフリカ
- その他中東とアフリカ
第9章 抗凝固薬企業の競合情勢
- 抗凝固薬市場の競合
- 提携・協力・合意
- 合併・買収
- 新製品の上市
- その他の開発
第10章 企業プロファイル
- 上位企業の市場シェア分析
- 市場集中度
- Aspen Holdings
- Pfizer Inc.
- Bristol-Myers Squibb Company
- GSK Plc
- Sanofi
- Bayer AG
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Company Limited
- Johnson & Johnson Services Inc.
- Eisai Co. Ltd
LIST OF TABLES
- Market Snapshot
- Drivers: Impact Analysis
- Restraints: Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- Analysis By Drug Category (USD MN)
- Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa) Market Sales By Geography (USD MN)
- Vitamin K Antagonist Market Sales By Geography (USD MN)
- Direct Thrombin Inhibitors Market Sales By Geography (USD MN)
- Heparin and Low Molecular Weight Heparin (LMWH) Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Analysis By Route of Administration (USD MN)
- Oral Anticoagulants Market Sales By Geography (USD MN)
- Injectable Anticoagulants Market Sales By Geography (USD MN)
- Analysis By Application (USD MN)
- Atrial Fibrillation/Myocardial Infarction (Heart Attack) Market Sales By Geography (USD MN)
- Deep Vein Thrombosis (DVT) Market Sales By Geography (USD MN)
- Pulmonary Embolism Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Global Anticoagulant Market Sales By Geography (USD MN)
- North America Market Analysis (USD MN)
- United States Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate By Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Anticoagulant Report
- Market Research Process
- Market Research Methodology
- Global Anticoagulant Market Size, By Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis By Drug Category
- Market Attractiveness Analysis By Route of Administration
- Market Attractiveness Analysis By Application
- Market Attractiveness Analysis By Region
- Value Chain Analysis
- Global Market Analysis By Drug Category (USD MN)
- Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa) Market Sales By Geography (USD MN)
- Vitamin K Antagonist Market Sales By Geography (USD MN)
- Direct Thrombin Inhibitors Market Sales By Geography (USD MN)
- Heparin and Low Molecular Weight Heparin (LMWH) Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Global Market Analysis By Route of Administration (USD MN)
- Oral Anticoagulants Market Sales By Geography (USD MN)
- Injectable Anticoagulants Market Sales By Geography (USD MN)
- Global Market Analysis By Application (USD MN)
- Atrial Fibrillation/Myocardial Infarction (Heart Attack) Market Sales By Geography (USD MN)
- Deep Vein Thrombosis (DVT) Market Sales By Geography (USD MN)
- Pulmonary Embolism Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
The global demand for Anticoagulant Market is presumed to reach the market size of nearly USD 89.95 Billion by 2032 from USD 40.1 Billion in 2023 with a CAGR of 9.39% under the study period 2024-2032.
Anticoagulants, generally called blood thinners, are chemical materials that prohibit or curtail coagulation of blood and lengthen the clotting period. Anticoagulants are used to abolish the chances of blood clots in the body. Blood clots are built when platelets glue together and proteins present in the blood bind together to create a solid lump. Anticoagulants cease the platelets from binding to one another and clotting proteins from adhering together. The market offers various types of anticoagulant drugs, and each drug functions by deterring various paths of blood coagulation. These drugs are primarily used for the high threat of blood clots, deep vein thrombosis, pulmonary embolism, and others. Besides, they are commonly used in the treatment of pulmonary embolism, atrial fibrillation, and managing the risk of stroke.
MARKET DYNAMICS
The global anticoagulants market is anticipated to grow at a substantial rate in the coming years, with the increasing plurality of diseases such as venous thromboembolism and cardiovascular disease across the globe. Moreover, the growing adoption of new oral anticoagulants, and maturing awareness of new techniques is boosting the market growth. Similarly, expanding obesity problems and geriatric population with the growing demand for contemporary therapeutics are predicted to affect the growth of the global anticoagulant market during the forecast period.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anticoagulant. The growth and trends of Anticoagulant industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Anticoagulant market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Category
- Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa)
- Vitamin K Antagonist
- Direct Thrombin Inhibitors
- Heparin and Low Molecular Weight Heparin (LMWH)
- Others
By Route of Administration
- Oral Anticoagulants
- Injectable Anticoagulants
By Application
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism
- Others
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Anticoagulant market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anticoagulant market include Aspen Holdings, Pfizer Inc., Bristol-Myers Squibb Company, GSK Plc, Sanofi, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Eisai Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. ANTICOAGULANT - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Category
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY DRUG CATEGORY
- 5.1. Overview By Drug Category
- 5.2. Historical and Forecast Data
- 5.3. Analysis By Drug Category
- 5.4. Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa) Historic and Forecast Sales By Regions
- 5.5. Vitamin K Antagonist Historic and Forecast Sales By Regions
- 5.6. Direct Thrombin Inhibitors Historic and Forecast Sales By Regions
- 5.7. Heparin and Low Molecular Weight Heparin (LMWH) Historic and Forecast Sales By Regions
- 5.8. Others Historic and Forecast Sales By Regions
6. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
- 6.1. Overview By Route of Administration
- 6.2. Historical and Forecast Data
- 6.3. Analysis By Route of Administration
- 6.4. Oral Anticoagulants Historic and Forecast Sales By Regions
- 6.5. Injectable Anticoagulants Historic and Forecast Sales By Regions
7. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY APPLICATION
- 7.1. Overview By Application
- 7.2. Historical and Forecast Data
- 7.3. Analysis By Application
- 7.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack) Historic and Forecast Sales By Regions
- 7.5. Deep Vein Thrombosis (DVT) Historic and Forecast Sales By Regions
- 7.6. Pulmonary Embolism Historic and Forecast Sales By Regions
- 7.7. Others Historic and Forecast Sales By Regions
8. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
- 8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
- 8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
- 8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
- 8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE ANTICOAGULANT COMPANIES
- 9.1. Anticoagulant Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10. COMPANY PROFILES OF ANTICOAGULANT INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Aspen Holdings
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
- 10.4. Pfizer Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
- 10.5. Bristol-Myers Squibb Company
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
- 10.6. GSK Plc
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
- 10.7. Sanofi
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
- 10.8. Bayer AG
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
- 10.9. Boehringer Ingelheim International GmbH
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
- 10.10. Daiichi Sankyo Company Limited
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
- 10.11. Johnson & Johnson Services Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
- 10.12. Eisai Co. Ltd
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
